Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients

Turken M., Kose Ş., Ergun N. C., Tatar B.

ARAB JOURNAL OF GASTROENTEROLOGY, vol.21, no.4, pp.278-281, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.1016/j.ajg.2020.08.005
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.278-281
  • Keywords: Hepatitis C virus, Treatment, Response, PEGYLATED INTERFERON, VIRUS, EFFICACY
  • Dokuz Eylül University Affiliated: No


Background and study aims: Rapid virologic response (RVR) is defined as undetectable hepatitis C virus (HCV) RNA in serum after 4 weeks of treatment for chronic hepatitis C (CHC). Paritaprevir/ritonavir/ombi tasvir (PRO) and/or dasabuvir (D), with or without ribavirin [PRO (D) ribavirin], which are direct-acting antivirals (DAAs), is the currently approved treatment regimen for CHC genotype 1; this regimen can also be used in patients with end-stage renal failure (ESRF). In this study, we aimed to evaluate the effect of pretreatment factors on RVR in patients treated with PRO (D) +/- ribavirin.